Skip to Main Content

Issues

ISSN 2397-8554
EISSN 2397-8562
In this Issue

Cancer Immune Resistance

Review Articles

Emerging Topics in Life Sciences (12 December 2017) 1 (5): 411–419.
Emerging Topics in Life Sciences (12 December 2017) 1 (5): 421–428.
Emerging Topics in Life Sciences (12 December 2017) 1 (5): 429–445.
Emerging Topics in Life Sciences (12 December 2017) 1 (5): 447–456.
Emerging Topics in Life Sciences (12 December 2017) 1 (5): 457–470.
Emerging Topics in Life Sciences (12 December 2017) 1 (5): 471–486.
Emerging Topics in Life Sciences (12 December 2017) 1 (5): 487–492.
Emerging Topics in Life Sciences (12 December 2017) 1 (5): 493–500.
Emerging Topics in Life Sciences (12 December 2017) 1 (5): 501–508.
Emerging Topics in Life Sciences (12 December 2017) 1 (5): 509–515.
  • Cover Image

    Cover Image

    issue cover

    Mapping gene signatures according to their expression in different immune landscapes of breast (BRCA), lung (LUAD) and colon (COAD) carcinoma, and melanoma (SKCM); signatures selectively expressed in the immune-active (ICR4) landscape are shown in red, those selectively expressed in the immune-silent (ICR1) landscape are shown as blue and those that are ubiquitously expressed independent of immune landscape are white. The image is based on Figure 1 in this issue's opening article (Lu et al., pages 411–419) in which the authors look at how cancer cells go through a conserved evolutionary bottleneck facing a Two-Option Choice to evade recognition by the immune competent host: they can either adopt a clean oncogenic process devoid of immunogenic stimuli (immune-silent tumors) or display an entropic biology prone to immune recognition (immune-active tumors).

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal